openPR Logo
Press release

Huge Growth Demand In Emerging Trends Of Medical Melanoma Drugs Market : Industry Analysis & Outlook (2016 - 2023)

05-29-2017 02:50 PM CET | Health & Medicine

Press release from: Transparecny Market Research

Huge Growth Demand In Emerging Trends Of Medical Melanoma Drugs

Melanoma is a form of skin cancer. Some of the major risk factors for melanoma are high levels of exposure to ultraviolet (UV) light leading to blistering sunburns, especially among population groups who are either in countries, which are in proximity to the equator or at very high altitudes.

According to the American Academy of Dermatology, the prevalence of melanoma is gradually increasing and rapidly spreads to other parts of the body. However, if melanoma is detected at an early stage i.e. in situ or stage 0. In this stage, the cure rate with surgical removal is nearly 100i% without any delays in seeking treatment; the survival rates from the disease are nearly 100 percent. When melanoma has spread to other body parts or has penetrated deeper into the skin or spreads, the treatment often becomes more complex. Hence, the systemic drug therapy for melanoma largely depends on the properties and stage at which melanoma is detected.

Obtain Report Details @ http://www.transparencymarketresearch.com/melanoma-drugs-market.html

Since, 2011 various drugs have received FDA approval for treatment of melanoma. The melanoma drugs market has been segmented based on type of drug therapy into chemotherapy, immunotherapy and, targeted therapy. Immunotherapy works on the mechanism of stimulating persons own immune system response to distinguish cancer cells from normal cells more efficiently. A number of types of immunotherapy treatments can be used to treat melanoma. During the past few years, many new immunotherapy drugs for melanoma have entered the market. Immunotherapy drugs for melanoma include Keytruda(pembrolizumab) and Opdivo (nivolumab) which got FDA approval in 2014. Above mentioned drugs target PD-1, a protein on immune system cells called T cells. By blocking PD-1 protein, these drugs increase the immune response of the body against melanoma cells. Recently, the FDA approval of Yervoy (ipilimumab) in October 2015 has opened new market opportunities for market expansion of immunotherapy drugs in melanoma drugs market. Ipilimumab (Yervoy) is also another type of drug that upsurges immune response. However, it blocks CTLA-4, another protein on T cells.

These drugs are given as an intravenous (IV) infusion every 2 or 3 weeks. This results in shrinking of tumor. This treatment can help number of people with stage IV melanoma to live longer. However, it’s not yet clear if these drugs can completely cure melanoma.

These drugs act as checkpoint inhibitors to fight against melanoma cancer. In addition, there is a strong pipeline for melanoma treatment drugs under development by major key players and other new entrants in this market. Thus, taking into consideration the strategic new product launches after FDA approval the melanoma drugs market is expected to grow exponentially.

Similarly the Cytokines are proteins in the body that increase the immune system. Artificial cytokines, such as interferon-alfa and interleukin-2 (IL-2), are occasionally used in patients with melanoma.

When chemotherapy drugs fail to deliver positive results in melanoma patients, targeted therapy drugs are administered to them. The targeted therapy drugs include BRAF inhibitors such as Zelboraf (vemurafenib) and Tafinlar (dabrafenib). The BRAF drugs work on the mechanism of shrinking tumors among those metastatic melanoma patients who have undergone genetic mutation. They are found to increase the progression free survival rate of patients. The MEK inhibitors such as trametinib (Mekinist) and cobimetinib (Cotellic) block the MEK proteins. In November 2015, Cotellic (cobimetinib) of Genentech Inc. received approval from FDA for the treatment of BRAF V600E or V600K melanoma. Generally Cotellic is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma.

On October 27th 2015, Amgen Inc.’s Oncolytic virus therapy for a deadly form of skin cancer/ melanoma was approved by U.S. FDA. The drug is known as talimogene laherparepvec, or T-vec, was cleared as a treatment for melanoma lesions in the skin and lymph nodes that can’t be removed completely by surgery. According to FDA brand-name of the drug is Imlygic. It uses adapted version of the herpes simplex virus to attack cancerous cells. After being injected into the tumor, the virus replicates until it causes the cells to breach and it results in provoking an immune system response that communicates the body to recognize the cancer.

Targeted therapy drugs have lower severity of side effects compared to other melanoma cancer drugs. However, despite of the new market opportunities created as a result of recent FDA approvals, some of the major restraints in the market are attributed to the lack of innovative and successful therapies in the market to reduce the risk of mortality of advanced metastatic melanoma patients. Thus, targeted therapy and their combinations could lead the melanoma drugs market and play a potential role in driving in melanoma drug market.

Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8443

Some of the major players in this market include Amgen, Inc., Bristol-Myers Squibb, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech Inc. Janssen Biotech, Inc., and Novartis International AG. Pfizer, Vical and ZIOPHARM.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huge Growth Demand In Emerging Trends Of Medical Melanoma Drugs Market : Industry Analysis & Outlook (2016 - 2023) here

News-ID: 554885 • Views:

More Releases from Transparecny Market Research

HAZMAT Packaging Market Share, Trends, Growth, Forecast By 2027
HAZMAT Packaging Market Share, Trends, Growth, Forecast By 2027
The global HAZMAT Packaging Market is estimated to flourish at a CAGR of 5.8% from 2024 to 2027. The overall HAZMAT Packaging industry delivers an in-depth systematic framework and competitive outlook of the HAZMAT Packaging Market from a worldwide perspective. The report starts with a summary of the market, chain structure, and the past as well as current market size. Also, the growth opportunities prevalent in the market in the coming
Push Pull Closures Market Will Generate New Growth Opportunities by 2027 with Top Key Players - Closure Systems International, Inc., O. Berk Company, LLC, Silgan Plastic Closures Solutions
Push Pull Closures Market Will Generate New Growth Opportunities by 2027 with To …
The global Push Pull Closures Market is estimated to flourish at a CAGR of 4.8% from 2024 to 2027. The overall Push Pull Closures industry delivers an in-depth systematic framework and competitive outlook of the Push Pull Closures Market from a worldwide perspective. The report starts with a summary of the market, chain structure, and the past as well as current market size. Also, the growth opportunities prevalent in the market
PET Preform Machines Market Estimated to Touch USD 14.1 billion at a CAGR of 6.0% by 2031
PET Preform Machines Market Estimated to Touch USD 14.1 billion at a CAGR of 6.0 …
The global PET Preform Machines Market has been sailing through robust waters, witnessing a valuation of US$ 8.3 Bn 2022. As we set our sights on the horizon, the market is poised to embark on a journey of steady growth, with a projected Compound Annual Growth Rate (CAGR) of 6.0% from 2023 to 2031. By the end of 2031, the industry is expected to anchor at an impressive US$ 14.1
Flexible Packaging Paper Market Share, Trends, Growth, Forecast By 2029
Flexible Packaging Paper Market Share, Trends, Growth, Forecast By 2029
The global Flexible Packaging Paper Market has been sailing through robust waters, witnessing a valuation of US$ 47.5 Bn 2021. As we set our sights on the horizon, the market is poised to embark on a journey of steady growth, with a projected Compound Annual Growth Rate (CAGR) of 4.1% from 2023 to 2029. By the end of 2029, the industry is expected to anchor at an impressive US$ 65.2

All 5 Releases


More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding